Experts Demand Inclusion of Pregnant and Breastfeeding Women in Clinical Research
Medical experts are issuing a stark warning that pregnant women and breastfeeding mothers must be included in clinical trials to ensure they can safely access vital medicines. The British Pharmacological Society (BPS) has released a new position statement calling for urgent reforms to address significant gaps in evidence-based guidance on medication use during pregnancy and lactation.
Critical Information Gap Leaves Women Vulnerable
The BPS highlights that approximately 80% of women in the United Kingdom take at least one medication during pregnancy or while breastfeeding. However, these women have historically been excluded from clinical trials, creating substantial deficiencies in safety and efficacy data. This exclusion has resulted in widespread uncertainty, fear, and inconsistent advice for patients managing chronic conditions during these critical periods.
Professor Cherry Wainwright, president of the British Pharmacological Society, emphasized the severity of the situation: "The current landscape leaves too many pregnant women navigating treatment without the clear, evidence-based guidance they deserve. Decades of excluding pregnant women from clinical research have created avoidable gaps in safety data, leading to uncertainty, delayed treatment, or unnecessary discontinuation of essential medicines."
Skewed Risk Communication and Training Deficiencies
The society notes that guidance provided to pregnant women often disproportionately focuses on medication risks rather than potential benefits. This imbalanced communication can lead to harmful outcomes, including untreated medical conditions that pose dangers to both mother and child.
The BPS has outlined several key recommendations to address these issues:
- Implement more inclusive research protocols that safely include expectant and breastfeeding women where appropriate
- Develop clear, balanced, and accessible information resources for patients
- Enhance training programs for healthcare professionals to improve guidance quality
Changing Perspectives on Research Ethics
Professor Catriona Waitt, NIHR professor of clinical pharmacology and global health at the University of Liverpool, explained the evolving ethical perspective: "For quite a long time, people felt that maybe doing research in pregnancy was risky, but actually, the general perspective has changed over the years. Rather than protecting women from research, we should protect them through research."
Professor Waitt detailed three problematic scenarios resulting from inadequate data:
- Women may avoid necessary medication, risking untreated disease complications
- Breastfeeding mothers might discontinue nursing, depriving both mother and baby of potential benefits
- Women who do take medication often experience significant anxiety due to uncertainty
Limited Evidence Base Compared to Other Populations
Dr. Emma Magavern, clinical lecturer in clinical pharmacology at Queen Mary University of London, highlighted the comparative data deficiency: "Most women take medication while pregnant or breastfeeding, but the data underpinning safety and effectiveness is quite limited compared to other population groups. Pregnant and breastfeeding women are often not included in clinical trials, which are the traditional way we determine which medicines are safe and effective."
Dr. Magavern further noted that risk-benefit communications have become skewed, with excessive emphasis on fetal risks overshadowing the significant dangers of inadequately treating maternal medical conditions during pregnancy and breastfeeding.
The British Pharmacological Society's position represents a significant shift in medical research ethics, advocating for greater inclusion rather than exclusion of pregnant and breastfeeding women from clinical studies to ensure better health outcomes for both mothers and their children.
